It has been reported that the existence of a TK network composed of the tyrosine AXL, Lyn and SYK, promotes cell resistance to nilotinib treatment and drives Bcr–Abl-independent CML cell proliferation. The gene discussed is LYN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.